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Abstract Interleukin-4 (IL-4) is a pleiotropic cytokine, which
acts on both hematopoietic and non-hematopoietic cells, through
different types of receptor complexes. In this study, we report
that in human B cells, IL-4 caused rapid phosphorylation of
Janus kinase (JAK) 1 and JAK3 tyrosine kinases. In keratino-
cytes, the hematopoietic-specific receptor common Qc chain is not
expressed and the IL-13 receptor K1 (IL-13RK1) participates in
IL-4 signal transduction. In keratinocytes, IL-4 induced JAK1
and JAK2 phosphorylation but, unlike in immune cells, IL-4 did
not involve JAK3 activation for its signaling. In both cell types,
IL-4 induced phosphorylation and DNA binding activation of the
signal transducer and activator of transcription (STAT) 6
protein. Furthermore, IL-4 stimulation of keratinocytes also
induced tyrosine phosphorylation of STAT3 which was found to
bind to the phosphorylated IL-13RK1. STAT3 however did not
significantly translocate to the nucleus, nor did it bind with high
affinity to target DNA sequences.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Interleukin-4 (IL-4) is a pleiotropic cytokine, which evokes
a high variety of biological responses by binding to a high
a⁄nity receptor complex. IL-4 receptors (IL-4R) are ex-
pressed in low numbers on a wide range of cell types, includ-
ing T and B lymphocytes, monocytes, granulocytes, ¢bro-
blasts, epithelial and endothelial cells. Cross-linking studies
have shown that IL-4 could bind to three molecular species
of 140 kDa, 70^75 kDa and 65 kDa, indicating a multimeric
structure of IL-4R [1]. The 140 kDa IL-4 binding protein (IL-
4RK) is expressed ubiquitously. The 65 kDa protein represents
the IL-2RQc chain, a common component of other cytokine
receptors [2^5], which increases by 2^3-fold the a⁄nity of IL-4
for its receptor in lymphoid cells [6] and participates in some
of the IL-4-mediated events [2]. The lack of Qc chain expres-
sion on human renal carcinoma cells, which nevertheless e⁄-
ciently bind IL-4 [7] and respond to IL-4 [8], suggests the
participation of another subunit in the IL-4R. In cells lacking
Qc, IL-4 signal transduction is thought to mobilize either ho-
modimerization of IL-4RK or heterodimerization of IL-4RK
with either one or two IL-13R chains [4,9,10]. Two IL-13RK
cDNAs have recently been cloned and both encode glycopro-
teins of 70^75 kDa [11^13].
These receptor subunits do not contain any consensus se-
quences encoding tyrosine or serine/threonine kinases. En-
gagement of IL-4 with its receptor triggers the Janus family
kinases (JAK). Although the phosphorylation level of individ-
ual JAK depends upon the cell type studied, tyrosine phos-
phorylation of all the JAKs (JAK1, JAK2, JAK3, TYK2) has
been reported after IL-4 binding [1]. It has been shown that
the IL-4RK associates with JAK1 [14] and the Qc associates
with JAK3 [15,16]. In response to IL-4, tyrosine phosphory-
lation of members of the signal transducer and activator of
transcription (STAT) family has been described. STAT6 acti-
vation appears to be a common feature of IL-4 signaling,
regardless of the cellular system studied [17].
We report here that the composition of IL-4R di¡ers be-
tween keratinocytes and lymphocytes. In lymphocytes, IL-4
signal transduction occurs through an IL-4RK/Qc complex.
In keratinocytes, in which Qc is not expressed, our results in-
dicate that IL-13RK1 participates to the IL-4R complex.
These di¡erences in the receptor composition lead to distinct
proximal events in IL-4 signaling. Thus, treatment of lympho-
cytes with IL-4 resulted in tyrosine phosphorylation of JAK1
and JAK3, whereas JAK1 and JAK2 were activated in kera-
tinocytes. In addition, there was a rapid induction of DNA
binding protein complexes containing STAT6 which was ty-
rosine-phosphorylated in the two cell lines. Interestingly, in
keratinocytes, STAT3 underwent partial activation in that it
appears to be tyrosine-phosphorylated but does not translo-
cate signi¢cantly to the nucleus.
2. Materials and methods
2.1. Cell culture
Keratinocytic cell lines (A431 and SVK14) were cultured in DMEM
supplemented with antibiotics (50 Wg/ml penicillin, 50 Wg/ml strepto-
mycin), with 1 mM sodium pyruvate and with 10% fetal calf serum.
Hematopoietic cell lines (Ramos B lymphocytes, Kit 225 T lympho-
cytes) were cultured in RPMI supplemented with antibiotics (50 Wg/ml
penicillin, 50 Wg/ml streptomycin), and with 10% fetal calf serum.
2.2. Antibodies and reagents
Human recombinant IL-4, a generous gift of Dr. N. Vita (Sano¢,
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France), was added to the culture media at a ¢nal concentration of
50 ng/ml. Epidermal growth factor (EGF) was purchased from Sigma
and used at a ¢nal concentration of 100 ng/ml.
Anti-JAK1 polyclonal antibodies (06-272), anti-JAK2 polyclonal
antibodies (06-255) and anti-P-Tyr monoclonal antibodies were from
UBI. Anti-STAT3 (C-20), anti-STAT6 (S-20) and anti-JAK3 (C-21)
polyclonal antibodies were from Santa Cruz.
2.3. Reverse transcriptase polynucleotide chain reaction (RT-PCR)
To analyze expression of the various IL-4R chains, total RNA was
extracted with Trizol (Life technologies) as described by the manufac-
turer. Primer pairs speci¢c for the di¡erent component were: 5P-GC-
GTCTCCGACTACATGAGC (sense) and 5P-GGTTGCTCCAGGT-
CAGCAGC (antisense) for IL-4RK, 5P-CAGCCTACCAACCTCAC-
TCT (sense) and 5P-GTCCTGGAGCTGAACAACAA (antisense) for
Qc, 5P-AGGATGACAAACTCTGGAG (sense) and 5P-CTCAAGGT-
CACAGTGAAGG (antisense) for IL-13RK1, 5P-ATACCTTTGG-
GACTTATTCC (sense) and 5P-TGAACATTTGGCCATGACTG
(antisense) for IL-13RK2.
2.4. Immunoprecipitation
Cells were lysed in a RIPA bu¡er containing 50 mM Tris^HCl,
pH 7.5, 1% Triton X-100, 50 mM NaCl, 50 mM NaF, 10 mM
NaPP, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 10 Wg/ml apro-
tinin, 10 Wg/ml leupeptin, 10 Wg/ml pepstatin. The cell lysates were
clari¢ed by centrifugation. Five-hundred Wg of total protein was in-
cubated with appropriate antibodies. The immunoprecipitates were
recovered with protein A-Sepharose beads at 4‡C for 1 h, washed,
resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a Hybond-C extra membrane (Amer-
sham). The blots were then hybridized with the appropriate anti-
bodies.
2.5. A⁄nity puri¢cation of DNA binding proteins
Nuclear extracts were prepared as described for electrophoretic
mobility shift assay (EMSA). The oligonucleotide sequences used
were derived from the high a⁄nity sis-inducible element (SIE) of
the c-fos gene (SIE m67), sense: 5P-CATTTCCCGTAAATC [18]
and from Q-interferon-activated sequence (GAS), sense: 5P-GTATTT-
CCCAGAAAAGGAAC [19]. DNA binding proteins were isolated
from 1 mg of nuclear extracts by incubation at 4‡C for 1 h with
3 Wg double-stranded 5P-biotinylated oligonucleotide coupled to 100
Wl of a 50% suspension of streptavidin-agarose (Sigma). Complexes
were washed in binding bu¡er and eluted by boiling in reducing sam-
ple bu¡er. Bound proteins were separated on 10% SDS-PAGE and
Western blotting was performed as previously described.
2.6. Glutathione S-transferase (GST) fusion proteins and GST pull
down experiments
A GST-IL-13RK1 intracytoplasmic domain fusion protein was con-
structed as follows. A plasmid encoding IL-13RK1 was kindly pro-
vided by Dr. N. Vita (Sano¢, France) and was used as a template to
amplify the intracytoplasmic domain that was then cloned in a Bam-
HI-EcoRI-linearized PGEX-2T. For this purpose, we used the follow-
ing pair of primers: 5P-ATGCGGATCCGAGGATGACAAACTC
(sense) and 5P-GCATGAATTCCTGAGAGGCTTTCTT (antisense).
GST fusion proteins were produced either in BL21 or in BL21 ex-
pressing the tyrosine kinase Elk and immobilized on glutathione
(GSH)-Sepharose beads. 2.5 mg of cellular extracts prepared in bu¡er
used for immunoprecipitation was rocked with coupled beads over-
night at 4‡C. The beads were washed twice in lysis bu¡er, boiled in
sample bu¡er and bound proteins were analyzed by Western blotting.
2.7. Immuno£uorescence studies
Cell monolayers grown on coverslips were rinsed twice in phos-
phate-bu¡ered saline (PBS) and ¢xed in 2% formaldehyde/PBS. After
two additional rinses, cells were permeabilized with 1% Triton X-100
(in PBS) and then washed in 0.1% Tween 20. Non-speci¢c protein
adsorption was blocked by a 30 min incubation with 2% bovine serum
albumin (BSA)/PBS. Samples were then incubated with primary anti-
bodies (1:200 in 2% BSA/PBS) for 1 h (22‡C), washed and incubated
with secondary antibodies (FITC-conjugated goat anti-rabbit antibod-
ies, 1:300, Nordic) for 30 min. These samples were washed and exam-
ined at a magni¢cation of U40 under a Zeiss LSM410 confocal mi-
croscope.
3. Results
3.1. Expression of IL-4R components in keratinocyte and in
lymphoid cell lines
IL-4 is a pleiotropic cytokine which acts on hematopoietic
and non-hematopoietic cells, with di¡erent biological activ-
ities. Di¡erent receptor chains, IL-4RK, Qc, IL-13RK1 and
IL-13RK2 have been described to participate in the composi-
tion of multiple forms of IL-4R. We therefore analyzed the
expression of the di¡erent chains by RT-PCR in two human
keratinocytic cell lines (A431, SVK14) and in two human
lymphoid cell lines, Ramos (B lymphocytes) and Kit 225 (T
lymphocytes). The results presented in Fig. 1 indicate that
whereas IL-4RK was present in all cell lines tested, this is
not the case for the other putative components of IL-4R.
As expected, expression of the hematopoietic-speci¢c Qc chain
was restricted to lymphocytes, and no expression of this chain
was observed in keratinocytes. Expression of the IL-13RK1
chain was observed in keratinocytes whereas no expression
of this chain was detectable in B lymphocytes. The presence
of IL-13RK2 was only observed in A431 cell lines. These re-
sults suggested that IL-4 signaling in keratinocytes might oc-
cur through either IL-4RK homodimerization or heterodime-
rization with one (SVK14) or two chains (A431) of IL-13R
and in lymphocytes through heterodimerization of IL-4R and
Qc.
3.2. Activation of the JAK/STAT pathway in Ramos and in
A431 cells
Engagement of IL-4 with its receptor induced triggering of
the JAK pathway. We therefore examined the phosphoryla-
tion of the di¡erent JAKs in the two cell lines in which IL-4
signal transduction could be mediated either by IL-4R/Qc (Ra-
mos) or by IL-4R/IL-13RK (A431). Both cell lines were stimu-
lated by IL-4 and total cellular extracts were immunoprecipi-
tated with speci¢c JAK antibodies. Phosphorylation of these
proteins was monitored by anti-P-Tyr Western blotting. As
shown in Fig. 2A, in the two cell lines, tyrosine phosphoryla-
tion of JAK1 was observed after 10 min of IL-4 stimulation.
We then investigated whether JAK2 and/or JAK3 were ac-
tivated in both cell lines. Following cell stimulation with IL-4,
the anti-JAK2 antiserum immunoprecipitated a 130 kDa
phosphorylated protein from A431 cell extracts, whereas a
Fig. 1. Composition of the receptor for IL-4. Ampli¢cation of the
IL-4RK, Qc, IL-13RK1, IL-13RK2 mRNA was performed on total
RNA of the di¡erent cell lines. The sequences of the oligonucleoti-
des used to amplify the various chains and expected sizes of the
PCR products are indicated in Section 2.
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125 kDa phospho-protein was precipitated from Ramos cells
(Fig. 2B, upper). It has already been reported that many anti-
JAK2 antibodies cross-react with JAK3 proteins [20]. Thus,
reprobing the blot with anti-JAK2 antibodies clearly indicated
that the 130 kDa protein in A431 corresponded to JAK2 and
was not reactive with the anti-JAK3 antiserum (Fig. 2B, me-
dium panel). In contrast, JAK2 was detectable in B cells, but
was not tyrosine-phosphorylated. Western blotting with an
anti-JAK3 indicated that the phosphorylated protein migrat-
ing at 125 kDa was JAK3 (Fig. 2B, lower panel). These results
were further substantiated by JAK3 immunoprecipitation that
con¢rmed that upon IL-4 stimulation, JAK3 became tyrosine-
phosphorylated in Ramos cells and that it is not expressed in
A431 (Fig. 2C). Treatment of the two cell lines with IL-4
failed to induce tyrosine phosphorylation of TYK2 (data
not shown).
3.3. Phosphorylation of STATs
The current model of cytokine signaling proposes that upon
cytokine binding to its speci¢c receptor, JAKs phosphorylate
the receptor on tyrosine residues, forming a docking site for
STATs that then become phosphorylated by JAKs. IL-4 has
been shown to primarily induce the phosphorylation and ac-
tivation of STAT6 [17]. In some cellular model however, acti-
vation of other STATs has also been described. We therefore
investigated the phosphorylation of STATs in these two cell
lines by immunoprecipitation of cellular extracts from unsti-
mulated or IL-4-stimulated cells with speci¢c antibodies. We
observed a STAT6 phosphorylation (Fig. 3A) in the immuno-
precipitates from IL-4-stimulated cellular extracts of the two
cell lines. Interestingly, although some constitutive STAT3
tyrosine phosphorylation is observed, IL-4 clearly increased
the tyrosine phosphorylation of STAT3 in A431 cellular ex-
tracts (Fig. 3B). We have observed no phosphorylation of
STAT3 in Ramos (Fig. 3B) nor tyrosine phosphorylation of
the other STAT proteins in the two cell lines (data not
shown). Taken together, these observations strongly suggested
that the presence of IL-13RK1 in the IL-4R complex expressed
in A431 allowed for JAK2 activation and STAT3 phosphor-
ylation.
3.4. STAT3 interacts with phosphorylated IL-13RK1 chain
The Src homology 2 (SH2) domain of STAT factors is
believed to mediate both binding to the receptor at phospho-
tyrosine sites and dimerization with a second phosphorylated
STAT molecule [21]. Recruitment of STAT6 by IL-4 has been
Fig. 2. JAK phosphorylation in response to IL-4 treatment. Ramos
or serum-starved A431 cells were stimulated with IL-4 for 10 min
(+) or not (3). Cell extracts were immunoprecipitated (IP) with
anti-JAK antibodies. A: With anti-JAK1 antibodies followed by
Western blotting with anti-P-Tyr antibodies (upper). The blot was
then stripped and reprobed with anti-JAK1 antibodies (lower). B:
With anti-JAK2 antibodies followed by Western blotting with either
anti-P-Tyr antibodies (upper). Blots were then stripped and re-
probed with either anti-JAK2 antibodies (medium) or anti-JAK3
antibodies (lower). Molecular weights of tyrosine-phosphorylated
protein are indicated. C: With anti-JAK3 antibodies followed by
Western blotting with anti-P-Tyr antibodies (upper). Blots were then
stripped and reprobed with anti-JAK3 antibodies (lower).
Fig. 3. Phosphorylation of STAT3 and STAT6 in response to IL-4
treatment. Ramos and A431 cells were stimulated (+) or not (3)
with IL-4 for 10 min. Cell lysates were prepared and 500 Wg of total
protein was immunoprecipitated (IP) with either STAT6 (A) or
STAT3 (B) antibodies. After separation by SDS-PAGE and transfer
to nitrocellulose ¢lter, precipitated proteins were probed with anti-
phosphotyrosine antibodies (upper) and with the immunoprecipitat-
ing antibodies (lower).
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shown to depend on three consensus YK/QXF motifs in the
IL-4RK chain [22], and we hypothesized that the unique par-
ticipation of IL-13RK1 in the A431 IL-4R complex might be
responsible for STAT3 activation. In many cytokine recep-
tors, recruitment of STAT3 occurs through SH2 recognition
of a phosphotyrosine residue in the YXXQ consensus motif
[23]. A similar motif YEKQ is present at position 405 in the
IL-13RK1 sequence. We therefore examined whether a GST-
IL-13RK1, containing this consensus motif, could bind STAT3
in vitro. For this purpose, we constructed a GST-IL-13RK1
fusion protein and produced it either in a regular Escherichia
coli or in an E. coli strain that had been co-transformed with
the Elk tyrosine kinase, resulting in GST-IL-13RK1 being
phosphorylated on tyrosine residues. As shown in Fig. 4, nei-
ther GST alone nor the non-phosphorylated GST-IL-13RK1
fusion proteins were able to precipitate STAT3 from A431 cell
lysates. When the GST-IL-13RK1 was used as a tyrosine-
phosphorylated protein, a clearcut binding of STAT3 was
observed (lane 2, compared to lane 1). This association was
abolished by addition of phenyl phosphate, indicating that
this protein-protein interaction occurred through a phospho-
tyrosine residue of IL-13RK1 with the SH2 domain of STAT3.
Under the same conditions, STAT6 did not associate with
GST-IL-13RK1 whether phosphorylated or not (data not
shown).
3.5. Function and subcellular distribution of STAT3
STAT proteins are activated by tyrosine phosphorylation
which is required for dimer formation, nuclear translocation,
DNA binding and transcriptional activity in cells treated with
cytokines. The induction of DNA binding activity of STAT3
in the nuclei of IL-4-stimulated A431 cells was investigated,
using an m67 SIE oligonucleotide, derived from the SIE of the
c-fos promoter, which has been described to be a target se-
quence for STAT3 [24]. In this experiment, a biotinylated SIE
oligonucleotide coupled to streptavidin-agarose was used to
a⁄nity purify STAT3 from nuclear extracts of IL-4- or
EGF-stimulated A431 cells. Proteins were resolved by SDS-
PAGE and detected by Western blotting with anti-STAT3
antibodies. STAT3 protein was only detected in nuclear ex-
tracts from EGF-stimulated cells (Fig. 5A, a). This result
suggests that STAT3 is not present in the nucleus after IL-4
stimulation. If we used a biotinylated GAS oligonucleotide
instead of biotinylated SIE, and Western-blotted with anti-
STAT6 antibodies, we observed the presence of STAT6 in
nuclear extracts from IL-4-stimulated cells but not in EGF-
stimulated cells (Fig. 5A, b). The same results were obtained
by EMSA analysis (data not shown). Taken together, these
observations indicate that, although STAT3 is tyrosine-phos-
phorylated after IL-4 stimulation, no DNA binding activity of
this transcription factor could be detected.
In vitro DNA binding of transcription factors does not al-
ways re£ect their in vivo transcriptional activity. To assess the
transcriptional activation of STAT3 by IL-4 and EGF, luci-
ferase-based reporter construct containing a tetramer of the
acute-phase response element (APRE)/STAT3 upstream a
SV40 minimal promoter was used [25]. When this construct
was transfected into A431 cells, induction of the APRE/
STAT3 driven luciferase activity was only observed upon
EGF stimulation (10-fold). There was no modi¢cation of lu-
ciferase activity after IL-4 stimulation (data not shown).
These results are in agreement with the absence of DNA bind-
ing activity of STAT3.
Since neither DNA binding nor transcriptional activities of
STAT3 could be detected, we investigated the cellular local-
ization of STAT3 by immuno£uorescence assay, in compar-
Fig. 4. Association of STAT3 with phosphorylated GST-IL-13RK1
fusion protein. Cellular extracts from serum-starved A431 were
mixed with GST-IL-13RK1 (lane 1), tyrosine-phosphorylated GST-
IL-13RK1, noted P-GST-IL-13RK1 (lanes 2 and 3) or with GST
alone (lane 4) immobilized on GSH-Sepharose beads. In lane 3,
phenyl phosphate (PP) was added to the cell lysates at a concentra-
tion of 100 mM. After separation on SDS-PAGE and transfer, pro-
teins were blotted with an anti-STAT3 and anti-GST antibodies.
Fig. 5. IL-4 did not lead to a functional STAT3. A: STAT3 DNA
binding activity: serum-starved A431 were stimulated with IL-4 or
EGF for 10 min or not (3). DNA binding proteins were a⁄nity-pu-
ri¢ed from nuclear extracts with an agarose-coupled biotinylated
m67 SIE (a) or GAS (b) oligonucleotides. Bound proteins were sep-
arated by SDS-PAGE and detected with an anti-STAT3 (a) or anti-
STAT6 antibodies (b). B: Subcellular distribution of STATs: a and
b show STAT6 immunodetection in A431 cells in the absence (a) or
in the presence of IL-4 (b). c^e show immunodetection of STAT3
with no stimulation (c), or after IL-4 (d), or EGF (e) stimulation.
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ison with STAT6. In unstimulated cells, both STAT3 and
STAT6 resided predominantly in the cytoplasm (Fig. 5B, a
and c). When cells were stimulated with IL-4, STAT6 trans-
located quickly and massively to the nucleus (Fig. 5B, b). In
contrast, after IL-4 stimulation, STAT3 remained largely in
the cytoplasm, and it was only clearly detectable in the nu-
cleus of very few cells (Fig. 5B, d). In these experiments, EGF
served as a positive control and was found to induce the
nuclear translocation of STAT3 in almost every single cell
observed (Fig. 5B, e).
Altogether, these results showed that, although STAT3 is
tyrosine-phosphorylated, its nuclear translocation, and there-
fore its DNA binding and transcriptional activity, are not
activated by IL-4.
4. Discussion
Within the last few years, studies on the structure and sig-
naling capacity of the IL-4R have elucidated mechanisms
whereby IL-4 regulates its panoply of biological responses.
While the structure of IL-4R has been extensively studied, it
has not been fully characterized especially in non-immune
cells. Our data demonstrate that the IL-4R complex in human
keratinocytes is di¡erent from that expressed in lymphocytes.
Unlike lymphocytes, keratinocytes do not express the hema-
topoietic cytokine receptor common Qc. Characterization of
IL-4R, reported in a larger number of cell lines, indicated
that only hematopoietic cells signi¢cantly expressed Qc, where-
as there was no expression of this chain in any of the non-
hematopoietic tumor cell lines examined [26]. Di¡erent chains,
able to participate to the formation of the IL-4R, are ex-
pressed in keratinocytes. They are IL-4RK, IL-13RK1 and
IL-13RK2. Certain discrepancies concerning the expression
of IL-13RK2 in A431 cells have been reported. Whereas Caput
et al. described a low expression of the IL-13RK2 chain, Mur-
ata et al. reported no presence of this chain in the same cell
line [13,26]. Therefore, in keratinocytes, IL-4 is thought to
mobilize heterodimerization of one chain of IL-4R with either
one or two IL-13R chains. IL-13RK1 by itself does not bind
IL-4, but when expressed with IL-4RK, in transfected cells,
can induce high a⁄nity binding to IL-4. Co-transfection of
IL-4R with IL-13RK2 neither modulated IL-4 binding activity
nor allowed for STAT6 activation in response to IL-4, indi-
cating that IL-13RK2 seems dispensable for IL-4 signal trans-
duction [27]. Therefore, the di¡erent putative composition of
the IL-4R complexes strongly suggested that IL-4 signaling
pathways would be di¡erent according to the nature of the
receptor. Indeed, in keratinocytes (A431 cells), we have pre-
viously reported that the extracellular-regulated kinase path-
way was activated in response to IL-4 [28] in contrast to
lymphocytes [29].
In the present study, we have focused our investigation on
the JAK/STAT pathway in A431 and Ramos cell lines. In
Ramos, IL-4 stimulation leads to JAK1, JAK3 and STAT6
phosphorylation, as previously described in other hemato-
poietic cell lines [30^33]. In A431 cells, our data demonstrate
that IL-4 stimulation induces the activation of JAK1 and
JAK2 tyrosine kinases. In these cells, no expression of
JAK3 was observed. Previous results indicate that in contrast
to the other member of the JAK family, expression of JAK3 is
mainly observed in cells of lymphoid and myeloid lineages,
such as NK cells, T lymphocytes and activated monocytes
[32,34,35]]. Further studies have shown that a low level of
JAK3 could be observed in endothelial cells [36] or abnor-
mally expressed in transformed hematopoietic and epithelial
cell lines such as breast cancer cells [37,38].
In non-hematopoietic cells that lack Qc, it has been shown
that JAK1, JAK2 and TYK2 can be phosphorylated and
activated in response to IL-4 [8]. More recently, transfection
of CHO cells with the di¡erent putative components of IL-4R,
IL-4RK and/or IL-13RK indicates that the presence of IL-4R
and IL-13RK1 is required for JAK1 and JAK2 activation
leading to an optimal activation of STAT6 in response to
IL-4 [27].
The region of the IL-4RK chain between amino acids 557
and 667 has been shown to play an important role in activa-
tion of STAT6 after IL-4 stimulation, as it contains three
STAT6 SH2 binding consensus sequences YK/QXF [22]. A
STAT3 consensus motif YXXQ has been described in the
gp130 family [23]. A similar motif YEKQ is present in the
IL-13RK1, suggesting that this receptor chain could interact
with STAT3. Experiments with GST-IL-13RK1 fusion protein
tyrosine-phosphorylated in vitro clearly indicated that there is
an interaction between STAT3 and IL-13RK1. This interac-
tion is probably mediated through the SH2 domain of STAT3
with the phosphorylated tyrosine residue in the YpEKQ motif
in IL-13RK1, since it was disrupted in the presence of phenyl-
phosphate.
In addition to phosphorylation and activation of STAT6,
phosphorylation of STAT3 after IL-4 stimulation has been
reported in normal tonsil B cells [39]; whether IL-13RK1 is
responsible for this activation has not been investigated.
Although STAT3 is tyrosine-phosphorylated after IL-4
stimulation, we observed no DNA binding activity in nuclear
extracts nor transcriptional activity of this transcription fac-
tor. Furthermore, immuno£uorescence studies reported here
showed that although STAT3 translocation in response to
EGF is normal, IL-4 did not induce signi¢cant translocation
of STAT3 to the nucleus. The active nuclear import of a large
number of nuclear proteins, including STATs, occurs through
the Ran/importin pathway [40]. Molecules utilizing this nu-
clear import system require speci¢c nuclear localization se-
quences (NLS). Paradoxically, such NLS are not identi¢able
on STAT proteins [41]. The complete molecular events leading
to the translocation of STAT proteins are not fully under-
stood. Recent studies have reported that STAT tyrosine phos-
phorylation is not su⁄cient to allow its nuclear translocation.
STATs have been shown to interact with cellular components
which can be mitogen-activated protein kinase [42], GR [43],
PI3 kinase [44] and a number of nuclear transcription factors
[45], which could participate in the migration of STAT to the
nucleus. Moreover, the involvement of the chaperone GRP58
protein in regulating the transit of phosphorylated STAT3
from the cell membrane to the nucleus has been suggested
[46]. GRP58 has been described to be tyrosine-phosphorylated
by the Lyn kinase, suggesting the participation of extracellular
stimuli in this regulation [47]. Other possibilities that could
explain that STAT3 is present in the nucleus at a low level
after IL-4 stimulation could be proposed. For example, in
particular in the model of prolactin receptor, the number of
phosphorylated tyrosines on the receptor itself seems to play a
critical role in the activation of a certain cellular component
that modulates STAT5 complexes in the cytoplasm, control-
ling their nuclear entry [48]. Further studies will be required to
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determine how the structural organization of receptors and
subsequent activation of particular signaling pathways could
a¡ect STAT protein nuclear translocation.
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